Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 10/20 | 0.58 |
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15138969 | 0.86 | TAAR1 (0.53) | TAAR1MAOBHTR2AHTR7DRD2 | |
| SCHEMBL10078124 | 0.83 | TAAR1 (0.45) | TAAR1MAOBHTR2AHRH1HRH4 | |
| SCHEMBL15274994 | 0.78 | HTR7 (0.47) | TAAR1MAOBHTR2AHTR7DRD2 | |
| SCHEMBL14143850 | 0.77 | TAAR1 (0.41) | TAAR1 | |
| SCHEMBL5705697 | 0.77 | TAAR1 (0.60) | TAAR1HTR2ADRD2DRD1CYP2A6 | |
| Hydrochloric Acid SCHEMBL5366344 | 0.76 | TAAR1 (0.61) | TAAR1MAOBHTR2AHTR7DRD2 | |
| Hydrochloric Acid SCHEMBL4409416 | 0.75 | TAAR1 (0.58) | TAAR1MAOBHTR2ADRD2DRD1 | |
| SCHEMBL10287770 | 0.75 | TAAR1 (0.36) | TAAR1 | |
| SCHEMBL16675049 | 0.75 | CYP1A2 (0.42) | CYP2A6SMN1; SMN2 | |
| SCHEMBL16675057 | 0.75 | CYP1A2 (0.42) | CYP2A6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120322878-A1 | Polycationic Compounds And Uses Thereof | POLYMEDIX, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012158672-A2 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | POLYMEDIX, INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120258141-A9 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-10-11 | — | — | US | disclosed |
| US-8232428-B2 | Polycationic compounds and uses thereof | PolyMedix,Inc. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120115877-A1 | Facially Amphiphilic Compounds, Compositions, And Uses Thereof In Treating Cancer | POLYMEDIX, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8129566-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20120039945-A1 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110124664-A1 | Polycationic Compounds And Uses Thereof | POLYMEDIX, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| EP-2301349-A2 | Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer | The Trustees of The University of Pennsylvania (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20100298344-A1 | Polycationic Compounds And Uses Thereof | POLYMEDIX, INC. | 2010-11-25 | — | — | US | disclosed |
| US-7745662-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100081665-A1 | Anti-Malarial Compounds | CELLCEUTIX CORPORATION | 2010-04-01 | — | — | US | disclosed |
| US-20090239811-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | POLYMEDIX, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-7553876-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2009-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | TAAR1 4726/4885MAOB 3540/4885HTR2A 3984/4885 |
| US-20120115877-A1 | Facially Amphiphilic Compounds, Compositions, And Uses Thereof In Treating Cancer | LIPA, ABHD16A, SGMS1 | TAAR1 4003/4885MAOB 4461/4885HTR2A 4067/4885 |
| US-20100298344-A1 | Polycationic Compounds And Uses Thereof | VEGFA, VHL, PGF | TAAR1 4736/4885MAOB 4273/4885HTR2A 4728/4885 |
| US-20120258141-A9 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | TAAR1 2693/4885MAOB 2535/4885HTR2A 1915/4885 |
| US-20120039945-A1 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | TAAR1 2693/4885MAOB 2535/4885HTR2A 1915/4885 |
| US-20120322878-A1 | Polycationic Compounds And Uses Thereof | VEGFA, VHL, PGF | TAAR1 4736/4885MAOB 4273/4885HTR2A 4728/4885 |
| US-20110124664-A1 | Polycationic Compounds And Uses Thereof | VEGFA, VHL, PGF | TAAR1 4736/4885MAOB 4273/4885HTR2A 4728/4885 |
| US-20090239811-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | VEGFA, VHL, PGF | TAAR1 4736/4885MAOB 4273/4885HTR2A 4728/4885 |
| US-20100081665-A1 | Anti-Malarial Compounds | AADAC, ME2, HTRA2 | TAAR1 3166/4885MAOB 1906/4885HTR2A 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.